ENTtoday
  • Home
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Multimedia
    • Video
    • Audio
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
    • eNewsletters
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

The Role of Checkpoint Inhibitors in the Treatment of Head and Neck Cancer

by Jennifer L.W. Fink • September 18, 2016

  • Tweet
Print-Friendly Version
T lymphocyte cells (orange) surrounding a cancer cell.

T lymphocyte cells (orange) surrounding a cancer cell.
© Spencer Sutton / Science Source.COM

This year, the National Institutes of Health estimates that approximately 60,000 Americans will be diagnosed with head and neck cancer. Although survival rates have increased over the last 30 years, the five-year relative survival rate for oral and oropharyngeal cancers is still only approximately 60% percent. Otolaryngologists, surgeons, and medical and radiation oncologists have had little to offer to patients whose disease has progressed despite surgery, chemotherapy, and radiation—until now.

You might also like:

  • HPV-Positive Oropharnygeal Cancer Has Better Prognosis than Tobacco-Induced Cancer
  • A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment
  • Targeted Therapy a Potential Treatment for Head and Neck Cancer
  • When Should Surveillance Imaging Be Performed After Treatment for Head and Neck Cancer?
Explore this issue:
September 2016

In early August 2016, the U.S. Food and Drug Administration approved pembrolizumab (Keytruda, Merck Sharp and Dohme Corp.) for use in patients with recurrent or metastatic head and neck squamous cell carcinoma that is refractory to platinum-based chemotherapy. The drug received accelerated approval based on early data from the KEYNOTE-012 trial. Trial participants received 200 mg of pembrolizumab IV every three weeks for 24 months, or until disease progression or they reached intolerable toxicity. The overall objective response rate was 16%, with a complete response rate of 5%. The drug elicited response in both HPV-positive and HPV-negative tumors (24% vs. 16%). Eighty-two percent of those who responded to the medication did not have progression of disease for at least six months. Now, some patients are doing well more than two years out from their initial treatments (J Clin Oncol. 2016;34(suppl; abstr 6011)).

The traditional platform for treating head and neck has been a table with three legs, surgery, radiotherapy, and chemotherapy. Immunotherapy, in essence, brings a fourth leg to the table. —David Brizel, MD

Pembrolizumab is a checkpoint inhibitor, a drug that essentially unmasks tumor cells so the immune system can attack and destroy them. Specifically, pembrolizumab is a PD-L1 inhibitor; it inhibits the interaction of PD-L1, a protein on tumor cells and PD-1, a protein on T-cells. Checkpoint inhibitors “turn off the off switch, which has the net effect of turning the immune system back on,” said David Brizel, MD, Leonard Prosnitz Professor of Radiation Oncology at Duke University in Durham, N.C.

The idea of unleashing the immune system against cancer cells is not new. What is new is the hope that these medications are offering hope to patients who would otherwise have no options. Maura Gillison, MD, PhD, professor of medicine and Jeg Coughlin Chair of Cancer Research at The Ohio State University Comprehensive Cancer Center in Columbus, has seen remission following checkpoint inhibitor treatment in some of her patients.

Pages: 1 2 3 4 5 Single Page

Filed Under: Head and Neck, Home Slider, Special Report Tagged With: checkpoint inhibitors, head and neck cancer, immunotherapy, treatmentIssue: September 2016

You might also like:

  • HPV-Positive Oropharnygeal Cancer Has Better Prognosis than Tobacco-Induced Cancer
  • A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment
  • Targeted Therapy a Potential Treatment for Head and Neck Cancer
  • When Should Surveillance Imaging Be Performed After Treatment for Head and Neck Cancer?

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • How Writing Helps a Medical Resident Better Care for Patients
  • How Physicians Can Build a Network to Boost Their Career
  • How To Survive the First Year of Medical Residency
  • ACGME Revises Cap on Resident Work Hours
  • Ethical Implications of Burnout in Otolaryngology Residents
  • Popular this Week
  • Most Popular
  • Most Recent
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Counseling Patients on Safe Nasal Irrigation
    • Is There a Crisis in the Otolaryngology Match?
    • Weaning Patients Off of PPIs
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Short-and Long-Term Data Suggest Efficacy of Turbinate Ablation
    • Counseling Patients on Safe Nasal Irrigation
    • Artificial Intelligence and Machine Learning in Otolaryngology
    • Letter from the Editor: Peer Reviewing Sensational Headlines
    • Is Topical Epinephrine Safe for Hemostasis in Endoscopic Sinus Surgery?
    • Is it Safe to Kiss in Era of HPV Head and Neck Cancer ‘Epidemic’?

Polls

Is artificial intelligence an advantage for medicine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy

Visit: The Triological Society • The Laryngoscope • Triological Meeting Posters

Wiley
© 2019 The Triological Society. All Rights Reserved.
ISSN 1559-4939

This site uses cookies: Find out more.